[Acidifying therapy in the combined treatment of patients with liver cirrhosis].
Data are submitted of clinical and biochemical examination of patients with cirrhosis of the liver complicated by different type encephalopathy. Examined before treatment and after the course of therapy involving administration of the acidifying drugs normase, dufalak were patients presenting with manifestations of hepatodepressive syndrome, parenchymal, mixed-type portosystemic encephalopathy, with n = 27, 12, 23 and 38 respectively. Clinical, biochemical findings, time course of the ratio blood serum levels of anticerebrotoxic: cerebrotoxic amino acids (valin + leucine + isoleucine) allowed judgement about efficacies of the treatments administered. The results obtained showed high clinical benefit from treatment with normase and dufalak in patients with hepatodepressive syndrome and portal-systemic encephalopathy.
Chervak
I M
IM
D000596:Amino Acids / Q000097:blood / Q000187:drug effects; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006501:Hepatic Encephalopathy / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006975:Hypertension, Portal / Q000097:blood / Q000150:complications / Q000188:drug therapy; D007792:Lactulose / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008104:Liver Cirrhosis, Alcoholic / Q000097:blood / Q000150:complications / Q000188:drug therapy; D008105:Liver Cirrhosis, Biliary / Q000097:blood / Q000150:complications / Q000188:drug therapy; D008297:Male; D013577:Syndrome
D000596:Amino Acids; D005765:Gastrointestinal Agents; D007792:Lactulose